Kabra Drugs Limited: Audited FY26 Results Show Revenue Growth, Q4 Profit Decline

Revenue: ₹35.41 crore (Qtr Ended Mar'26) vs ₹30.42 crore (Qtr Ended Dec'25) | Net Profit: ₹1.06 crore (Qtr Ended Mar'26) vs ₹2.20 crore (Qtr Ended Dec'25)

Reader Takeaway: Revenue up, but Q4 profit down due to higher working capital and tax changes.

What just happened

Kabra Drugs Limited announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported revenue from operations of ₹35.41 crore for the March 2026 quarter, a 16.4% increase from ₹30.42 crore in the December 2025 quarter. However, net profit for the quarter saw a significant drop of 51.8%, falling to ₹1.06 crore from ₹2.20 crore in the previous quarter. For the full financial year, revenue stood at ₹92.74 crore. The company also transitioned to the concessional tax regime under Section 115BAA of the Income-tax Act, which impacted its tax expenses.

Why this matters

While the top line shows growth, the decline in quarterly profit despite higher revenue raises concerns. The substantial increase in trade receivables (₹70.78 crore) and trade payables (₹54.83 crore) has led to a negative operating cash flow of ₹-9.47 crore for the financial year. This divergence between profit and cash flow, coupled with accounting adjustments for leases under Ind AS 116, warrants close investor attention.

The backstory

This announcement provides the audited financial performance for the fiscal year ending March 2026. The company operates in the pharmaceutical sector, manufacturing and marketing drug formulations. The previous year's financial figures serve as a baseline for comparison, highlighting the recent shifts in working capital and profitability.

What changes now

Investors will closely monitor how Kabra Drugs manages its increased working capital. The ability to convert higher receivables into cash and manage payables efficiently will be crucial for future cash generation. The impact of the new tax regime and lease accounting standards will also continue to influence reported financials.

Risks to watch

The primary risk is the company's working capital management. A prolonged increase in receivables can tie up cash and affect liquidity. The decline in net profit margin in the latest quarter, despite revenue growth, needs careful examination.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Revenue (Qtr Mar'26): ₹35.41 crore (+16.4% QoQ)
• Net Profit (Qtr Mar'26): ₹1.06 crore (-51.8% QoQ)
• Revenue (FY26): ₹92.74 crore
• Operating Cash Flow (FY26): ₹-9.47 crore
• Trade Receivables (Mar'26): ₹70.78 crore (vs ₹0.60 crore Mar'25)
• Trade Payables (Mar'26): ₹54.83 crore (vs ₹0 crore Mar'25)

What to track next

Investors should track the company's subsequent quarterly results to see if the trend of rising receivables and payables continues, and more importantly, if operating cash flow improves. Monitoring the management's commentary on working capital management and business expansion strategies will be key.